

PRODUCT INFORMATION




Leniolisib

Item No. 28078

CAS Registry No.: 1354690-24-6
Formal Name: 1-[(3S)-3-[[5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin-4-yl]amino]-1-pyrrolidinyl]-1-propanone

Synonym: CDZ 173
MF: C₂₁H₂₅F₃N₆O₂
FW: 450.5
Purity: ≥98% (mixture of rotamers)
UV/Vis.: λ_{max}: 248 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Leniolisib is supplied as a crystalline solid. A stock solution may be made by dissolving the leniolisib in the solvent of choice, which should be purged with an inert gas. Leniolisib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of leniolisib in these solvents is approximately 20, 25, and 30 mg/ml, respectively.

Leniolisib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, leniolisib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Leniolisib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Leniolisib is an inhibitor of PI3Kδ (IC₅₀ = 0.011 μM).¹ It is selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC₅₀s = 0.244, 0.424, and 2.23 μM, respectively). It inhibits phosphorylation of the PI3K target Akt in Rat-1 fibroblasts expressing P13K p110δ with an IC₅₀ value of 0.056 μM. Leniolisib inhibits the mixed lymphocyte reaction (MLR), indicating inhibition of allogeneic T cell activation, in isolated human peripheral blood mononuclear cells (PBMCs) and isolated mouse splenocytes (IC₅₀s = 0.079 and 0.033 μM, respectively). It also inhibits PI3Kδ-dependent B cell activation and IgM-induced B cell proliferation in isolated mouse splenocytes. Leniolisib (3 and 10 mg/kg) reduces the production of rat anti-rat collagen antibodies, as well as reduces paw swelling and joint erosion in a rat model of collagen-induced arthritis.

Reference

1. Hoegenauer, K., Soldermann, N., Zécree, F., *et al.* Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors. *ACS Med. Chem. Lett.* **8**(9), 975-980 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM